Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007143433 - NANOPOROUS STENTS WITH ENHANCED CELLULAR ADHESION AND REDUCED NEOINTIMAL FORMATION

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

WHAT IS CLAIMED IS:
1. A medical device for insertion into a body, comprising a medical device having a porous surface exhibiting reduced neointimal formation compared to the same medical device lacking the porous surface.
2. The medical device for insertion into a body as in Claim 1, wherein the porous surface is a nanoporous surface.
3. The medical device for insertion into a body as in Claim 1, wherein the porous surface is a dealloyed surface.
4. The medical device for insertion into a body as in Claim 3, wherein the dealloyed surface is a nanoporous surface.
5. The medical device for insertion into a body as in Claim 1, wherein the medical device is a stent.
6. The medical device for insertion into a body as in Claim 5, wherein the stent is a coronary stent.
7. The medical device for insertion into a body as in Claim 1, wherein the medical device exhibits a reduced percentage area of stenosis compared to the same medical device lacking the porous surface.
8. The medical device for insertion into a body as in Claim 1, wherein the medical device lacks an elutable therapeutic agent.
9. The medical device for insertion into a body as in Claim 4, wherein the nanoporous surface contains at least one therapeutic agent.
10. The medical device for insertion into a body as in Claim 9, wherein the at least one therapeutic agent is selected from a group consisting of: actinomycin-D, batimistat, c-myc antisense, dexamethasone, paclitaxel, taxanes, sirolimus, tacrolimus and everolimus, unfractionated heparin, low-molecular weight heparin, enoxaprin, bivalirudin, tyrosine kinase inhibitors, Gleevec, wortmannin, PDGF inhibitors, AG1295, rho kinase inhibitors, Y27632, calcium channel blockers, sphingosine phosphate inhibitors, amlodipine, nifedipine, and ACE inhibitors, synthetic polysaccharides, ticlopinin, dipyridamole, clopidogrel, fondaparinux, streptokinase, urokinase, r-urokinase, r-prourokinase, rt-PA, APSAC, TNK-rt-PA, reteplase, alteplase, monteplase, lanoplase, pamiteplase, staphylokinase, abciximab, tirofiban, orbofiban, xemilofiban, sibrafiban, roxifiban, ABT-578, CCI-779, biolimus-A9, temsirolimus, anti-CD34 antibodies, mycophenolic acid, Vitamin E, omega-3 fatty acids, tempamine, and docetaxel, an agent for altering cytochrome P450 function, cyclosporine, an azole antifungal agent, itraconazole, ketoconazole, a macrolide antibiotic, clarithromycin, erythromycin, troleandomycin, an non-nucleoside reverse transcriptase inhibitor, delavirdine, a protease inhibitor, indinavir, ritonavir, saquinavir, ritonavir, grapefruit juice extract, mifepristone, nefazodone, an anti-restenosis agent, an anti-thrombogenic agent, an antibiotic, an anti-platelet agent, an anti-clotting agent, an anti-inflammatory agent, an anti-neoplastic agent, a chelating agent, penicillamine, triethylene tetramine dihydrochloride, EDTA, DMSA (succimer), deferoxamine mesylate, a radiocontrast agent, a radio-isotope, a prodrug, antibody fragments, antibodies, live cells, therapeutic drug delivery microspheres or microbeads, gene therapy agents, viral vectors and plasmid DNA vectors.